2020
DOI: 10.1101/2020.12.20.423718
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway

Abstract: Glioblastoma (GBM) is invariably resistant to temozolomide (TMZ) chemotherapy. Inhibiting the proteasomal pathway is an emerging strategy to accumulate damaged proteins and inhibit their lysosomal degradation. We hypothesized that bortezomib (BTZ) might sensitize GBM cells to TMZ. We examined change in autophagic flux after drug treatments and in combination with pharmacological inhibitors or CRISPR cas9 knockout of autophagy-related genes -5 and -7 (ATG5 and ATG7, respectively). Autophagic flux was increased … Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 65 publications
(80 reference statements)
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?